68 Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

Cancer Imaging

Wolfgang P. Fendler¹  Markus Schwaiger⁴  Tobias Maurer²  Matthias Eiber⁴  Wieland H. Sommer³ 

[1] Clinical Cancer Center Munich (CCM), Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians University of Munich, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians University of Munich, Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians University of Munich, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyDepartment of Nuclear Medicine, Ludwig-Maximilians University of Munich, Munich, Germany;Clinical Cancer Center Munich (CCM), Munich, GermanyKlinikum rechts der Isar, Department of Urology, Technische Universität München, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyKlinikum rechts der Isar, Department of Urology, Technische Universität München, Munich, GermanyKlinikum rechts der Isar, Department of Urology, Technische Universität München, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyKlinikum rechts der Isar, Department of Urology, Technische Universität München, Munich, Germany;Clinical Cancer Center Munich (CCM), Munich, GermanyGrosshadern Campus, Department of Clinical Radiology, Ludwig-Maximilians University of Munich, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyGrosshadern Campus, Department of Clinical Radiology, Ludwig-Maximilians University of Munich, Munich, GermanyGrosshadern Campus, Department of Clinical Radiology, Ludwig-Maximilians University of Munich, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyGrosshadern Campus, Department of Clinical Radiology, Ludwig-Maximilians University of Munich, Munich, Germany;Klinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyGerman Cancer Consortium (DKTK), Heidelberg, GermanyKlinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Munich, GermanyKlinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyGerman Cancer Consortium (DKTK), Heidelberg, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyKlinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyGerman Cancer Consortium (DKTK), Heidelberg, GermanyGerman Cancer Consortium (DKTK), Heidelberg, GermanyKlinikum rechts der Isar, Department of Nuclear Medicine, Technische Universität München, Munich, GermanyClinical Cancer Center Munich (CCM), Munich, GermanyGerman Cancer Consortium (DKTK), Heidelberg, Germany

关键词: Prostate cancer;    Prostate specific membrane antigen;    Positron emission tomography;   

DOI  :  10.1186/s40644-016-0072-6

来源: e-MED Ltd

【 授权许可】

Unknown